Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
-
br Introduction Arginase deficiency is a rare
2024-05-24
Introduction Arginase deficiency is a rare metabolic disorder resulting from a loss of arginase 1 (ARG1), the final enzyme in the urea cycle, which is the major pathway for the detoxification of ammonia in terrestrial mammals. ARG1 is expressed most prevalently in hepatocytes and red blood cells.
-
As the experimental procedure used
2024-05-24
As the experimental procedure used could reflect agonist-stimulation of both anterograde and retrograde APJ trafficking, as has been described for the δ-opioid peptide receptor (Zhang et al., 2006b, Zhang et al., 2006a), receptor internalization was more directly monitored by loading cell surface HA
-
EPSP analogs were retrieved from PubChem database and
2024-05-24
EPSP analogs were retrieved from PubChem database and docking procedure yielded about eight best binding analogs (Fig. 10). The selected molecules were further assessed for their theoretical Ki values using AUTODOCK software version 4. The predicted binding efficiency of retrieved analogs was estima
-
br Experimental section br Acknowledgements This work was fu
2024-05-24
Experimental section Acknowledgements This work was funded by the Italian Association for Cancer Research (AIRC IG18590 to A.A.), by “Fondi di Ateneo-University of Pisa” years 2009 and 2010 (E. N., S. N., E. O., and A. R.) and partially by the Unipi project P.R.A.2016_27 (E. N., E.O. and A. R.
-
There are several strengths and weaknesses of
2024-05-23
There are several strengths and weaknesses of the current investigation which merit consideration. Obviously, the current findings are important and less prone to bias than findings from traditional observational epidemiological studies, because causal investigations with the use of genetic variants
-
It is well known that
2024-05-23
It is well-known that TCDD is the most potent ligand of AhR and it regulates gene expression, such as CYP1A1, via activation of AhR (Mimura and Fujii-Kuriyama, 2003). Besides Tomblin et al. (2016) have recently shown that TCDD via AhR regulated L-type amino UCF 101 transporter 1 expression in MCF-7
-
These results from the present study are
2024-05-23
These results from the present study are summarized in Table 1. Eight drugs (doxorubicin, epirubicin, daunorubicin, idarubicin, irinotecan, imatinib, sunitinib and gefitinib) inhibited 5-HT-induced 5-HT3A and 5-HT3AB currents; three (irinotecan, topotecan and mitoxantrone) showed different responses
-
Pioneering studies on the immunomodulatory
2024-05-23
Pioneering studies on the immunomodulatory role of adenosine date back to the early ‘70 s of last century (Fig. 1), when the critical role of this nucleoside in shaping the development and the activity of several immune cell populations was first established [[18], [19], [20], [21], [22]]. This then
-
The total IgG concentration decreased from a
2024-05-23
The total IgG concentration decreased from a mean of 997 mg/100 ml before treatment to a mean of 696 after treatment in the MuSK+MG patients, and from a mean of 1736 mg/100 ml to a mean of 802 mg/100 ml in the AChR+MG patients (normal values 723–1685 mg/100 ml). This decrement was also statistically
-
br Discussion The clinical course of our patient
2024-05-23
Discussion The clinical course of our patient until May 2012 was rather typical of early onset AChR-MG. Later on, the pattern of the disease was more typical of MuSK-MG, as evidenced by the distribution of myasthenic weakness and the unprovoked exacerbations. The angiotensin 2 receptor blocker of
-
br LOX in pancreatic cancer LOX is a key
2024-05-23
5-LOX in pancreatic cancer 5-LOX is a key player in pancreatic cancer (PC) progression. The upregulation of 5-LOX mRNA has been observed in pancreatic adenocarcinoma (PDAC) and also in neoplastic pancreatic tissues (Kennedy et al., 2003). Higher levels of 5-LOX transcripts (messengers) are presen
-
While the direct effects of ARI lead to
2024-05-23
While the direct effects of 5-ARI lead to a dramatic MAPK Inhibitor Library in serum DHT levels, other laboratory values are also affected by 5-ARI use. Serum testosterone elevations are known to occur with both finasteride and dutasteride use, but values will typically remain within the normal lab
-
br Materials and methods br
2024-05-23
Materials and methods Results Discussion Despite the relative complexity of immunotherapy, such treatment may have an important role, in conjunction with other therapies in the treatment of cancer refractory to conventional treatments alone. Clinical studies have recently shown that adding
-
From a clinical utility standpoint this study showed that AR
2024-05-22
From a clinical utility standpoint, this study showed that AR can be useful in the GATA3-positive tumor of unknown origin setting. Epidemiologically, in this setting, the top 2 diagnoses in the differential diagnosis are metastatic carcinoma of breast origin or urothelial origin [18]. Seven out of 1
-
Aberrant or a sustained activation of AhR signaling pathway
2024-05-22
Aberrant or a sustained activation of AhR signaling pathway, triggered by exogenous toxic ligands such as dioxins, PAHs or polychlorinated biphenyls (PCBs), is a well-described biological process engaged during tumor initiation and/or promotion in various tissues (e.g. liver, lung, skin)(reviewed in
15376 records 99/1026 page Previous Next First page 上5页 96979899100 下5页 Last page